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Introduction: Current treatment of patients with an acute occlusion of a cranial or a coronary artery, in for exam-
ple ST segment elevation myocardial infarction (STEMI), consists of either thrombolysis or percutaneous inter-
vention. Various thrombolytic agents (tissue plasminogen activators) are used for reperfusion therapy in
patients with STEMI. However, their use may be associated with an increased risk of bleeding which is inherent
to their actionmechanism. Therefore, newmethods of coronary clot resolution are being studied in an attempt to
potentiate the efﬁcacy and reduce the side effects of thrombolytics. A new method is ultrasound mediated
thrombus dissolution, or sonothrombolysis. The current literature exploring sonothrombolysis is diverse in
size and quality. In this systematic review of the current literature, we describe cardiovascular applications of
sonothrombolysis in patients. A comparison to the neurovascular application in ischemic stroke is made, as
more research has been performed on patients suffering from stroke.
Methods: A systematic search was performed following the PRISMA guidelines using EMBASE and MEDLINE da-
tabases regarding sonothrombolysis in human ischemic stroke and acute myocardial infarction patients.
Results: 12 original case–control or randomized controlled trials using a combination of ultrasound and
microbubbles were found. 6 trials studied ischemic stroke, and 6 trials studied acute myocardial infarction.
Conclusion: This systematic review provides up to date information on the subject of sonothrombolysis.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The primary use of echo-contrast microbubbles is the improvement
of echographic images by enhancing the acoustic signal. Microbubbles
undergo stable cavitation or oscillation when targeted by a diagnostic
ultrasound beam of low intensity. This increases the diagnostic quality
of ultrasound images acquired in patients as more sound is returned
to the ultrasound probe and thus more information is available to the
clinician. However, additional therapeutic effects of microbubbles
have been discovered in the last two decades [1].
In contrast to diagnostic ultrasound, therapeutic ultrasound consists
of higher intensity ultrasound. The microbubble not only oscillates but
also violently bursts and erupts under the intense ultrasound pressure.n; (r)TPA, (recombinant) tissue
ention; CD, Color Doppler; PW,
5F 013, VU University Medical
etherlands. Tel.: +31 20 444
land Ltd. This is an open access articlThis violent reaction releases energy in the local environment [2]. Be-
cause of this energy release, the application of therapeutic ultrasound
as a method of clot destruction in the setting of acute myocardial
infarction and acute ischemic stroke has been the topic of intensifying
research in human studies [3–6]. If diagnostic and therapeutic ultra-
sound parameters are combined in the same probe, diagnostic ultra-
sound with a microbubble infusion can locate the occluded vessel and
is capable of visualizing replenishment of microbubbles in the vascula-
ture after application of a therapeutic ultrasound impulse (Fig. 1).
These high intensity impulses are almost always combined with a load-
ing or a continuous dose of ﬁbrinolytic agents and this method of treat-
ment is therefore often called sonothrombolysis [7]. Fibrinolytic agents,
unfortunately, have the downside of a relatively high occurrence of
bleeding as a side-effect. Bleeding is associated with adverse outcome,
for example inducing additional hemorrhagic stroke during treatment.
The primary goal of investigation into sonothrombolysis is to minimize
bleeding risk and maximize treatment efﬁcacy, while possibly reducing
treatment delay and achieving early revascularization. When
sonothrombolysis is combined with a low dose of antithrombotics,
equal efﬁcacy might be achieved while reducing bleeding risk.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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dose of ﬁbrinolytic agents is therefore needed. This can be achieved by
the use ofmicrobubbles [8,9], possibly evenwithout the use of a ﬁbrino-
lytic agent [10].
An example of an area inwhichmicrobubbles and sonothrombolysis
are being investigated clinically is in ischemic stroke patients [9,11].
After the discovery of a potential beneﬁcial effect of pulsed wave Dopp-
ler ultrasound combined with recombinant tissue plasminogen activa-
tor (rTPA) in patients with acute ischemic stroke [12], several studies
have now been performed investigating the effect of ultrasound and
rTPA in patients with ischemic stroke. Different ultrasound contrast
agents have been utilized in this setting, each with different composi-
tions, and include either lipid or galactose based agents containing ei-
ther atmospheric air or other gases. A clinical study compared
SonoVue® (Bracco)with Levovist® (Schering) in patientswith acute is-
chemic stroke. A total of 138 patients were included, randomly assigned
to treatment with either type of microbubbles. While both agents ap-
peared to improve stroke recanalization rates, there were no clinically
signiﬁcant differences in efﬁcacy and safety found between the two
types of microbubbles [13].
Several in-vivo and in-vitro tests have already been performed to
evaluate the efﬁcacy and safety of sonothrombolysis in the setting of
acute ST elevation myocardial infarction (STEMI). To date, only one
pilot study has been performed in patients who underwent randomized
treatment to placebo or sonothrombolysis prior to primary percutane-
ous coronary intervention (PCI) [14]. Other studies in STEMI patients
were restricted to ultrasound and (r)TPA; no microbubbles were used
except in the previously described pilot study.
PCI is nowadays the favored method of treatment in STEMI pa-
tients.While markedly decreasingmortality as a result from early re-
canalization, a signiﬁcant portion of patients suffers from a
phenomenon called no-reﬂow. While epicardial recanalization is
achieved, microvascular perfusion is limited. This microvascular ob-
struction has a multifactorial origin and is in part thought to consist
of microthrombi occurring as a result from the PCI. An additional
therapeutic ﬁeld of interest for the concept of sonothrombolysis is
the periprocedural treatment of these microthrombi occurring dur-
ing PCI [15–18].
Patients in need of quick revascularization, such as in ischemic
stroke or myocardial infarction, beneﬁt most from a method of treat-
ment in which the clot is dissolved quickly and safely. This systematic
review will focus on these patients and elaborate on the current use
and level of evidence regarding sonothrombolysis.Fig. 1. Increasing acoustic pressure using higher duty cycle amount creates cavitating micro
destroying emboli. These emboli would otherwise not be destroyed using TPA alone.2. Methods
2.1. Search strategies and selection criteria
Literature searcheswere performedusing the PubMed and Cochrane
database. Case–control studies or randomized controlled trials compar-
ing regular thrombolytic therapy and thrombolytic therapy using ultra-
sound with or without microbubbles were included. In this regard all
STEMI studies using thismethod of treatmentwere included. Studies re-
garding ischemic stroke were only included if they randomized treat-
ment for microbubbles. Only studies performed in human patients of
adult age written in English, German and Dutch were included in this
study. Keywords used in the search included sonothrombolysis, throm-
bolysis, microbubble recanalization,myocardial infarction,microbubble
ultrasound thrombolysis, thrombolysis microstreaming, thrombolysis
myocardial infarction, microspheres, coronary ultrasound thrombolysis
and microbubble ischemic stroke.
Studies using sonothrombolysis with microbubble treatment in pa-
tients with ischemic stroke patients are presented in Table 1. The stud-
ies concerning human sonothrombolysis in patients with STEMI are
summarized in Table 2.
2.2. Outline of the review
The use of sonothrombolysis in patients with ischemic stroke will
be reviewed ﬁrst. The second part will consist of the use of
sonothrombolysis in cardiology. Finally, future applications of
microbubble treatment will be discussed.
2.3. Studies
The clinical trials in ischemic stroke had a wide range of transducer
settings and frequencies and most of them compared treatment
with TPA alone, treatment combining rTPA with ultrasound and
microbubbles combined with ultrasound and rTPA (Table 1).
All studies in STEMI patients (Table 2) used either TPA or rTPA but
differed in the type of transducer used. Two studies were performed
using catheter-based intravascular ultrasound probes, three studies
used therapeutic transthoracic ultrasound and one pilot study used di-
agnostic transthoracic ultrasound. Only one pilot study administered
microbubbles in the acute STEMI setting, in a 15 minute infusion prior
to PCI. Although microbubbles were safely administered in this settingbubbles. Cavitation creates, amongst other effects, microstreaming which is capable of
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can be weaned from this study.2.4. Neurology
2.4.1. Sonothrombolysis in acute ischemic stroke
Alexandrov et al. were theﬁrst to describe a beneﬁcial effect of ultra-
sound on clot dissolution in stroke patients treated with rTPA under
transcranial Doppler monitoring [12]. A later publication by the same
group found a trend toward better outcome and earlier recanalization
when patients were randomized between treatment with TPA and ul-
trasound combined with TPA [19]. In-vitro studies have demonstrated
an enhancement of thrombolysis when microbubbles were added to
the treatment regimen [20,21]. Molina et al. compared three different
treatment regimens for ischemic stroke. Patients were included if treat-
ment started within 3 h after onset of ischemic stroke. Treatment with
TPA (n = 36) was compared with ultrasound and TPA (n = 37), and
the combination of TPA, ultrasound, and perﬂutren-lipid microbubbles
(n = 38). The TPA, ultrasound and microbubble group achieved the
highest amount of complete clot resolution (54.5%) compared to TPA
(23.9%) and TPA with ultrasound (40.8%), p = 0.038 [9].
Another study performed by Alexandrov et al. [22] used data from
the CLOTBUST trial [23] as historic control. Patients in both studies
were included if onset of stroke was within 3 h of presentation. This
study administered perﬂutren-lipid microbubbles, in combination
with transcranial Doppler and TPA, and showed encouraging results.
An increase of complete recanalization from 18% (TPA only, n = 63)
to 50% (TPA, ultrasound and microbubbles, n = 12) was observed
when ultrasound was combined with microbubbles. Furthermore, re-
canalization was sustained signiﬁcantly more often (42%) after 2 h
with the addition of microbubbles, compared with ultrasound and TPA
(38%, n = 63) and TPA alone (13%) (p= 0.003). The authors found ev-
idence that microbubbles might have permeated beyond the occlusion,
further enhancing the sonothrombolytic effect, while ultrasound and
TPA alone did not penetrate completely, but this was not clariﬁed in
the manuscript.
The same effectwas found by Perren et al. comparing the addition of
SonoVue® microbubbles (n = 11) to a treatment regimen with rTPA
and ultrasound (n=15) in acute stroke patients. Patients were only in-
cluded if treatment with intravenous rTPA and ultrasound monitoring
already showed some effect and patients were no longer eligible to re-
ceive intra-arterial rTPA. Patients receivedmicrobubbles only if a duplex
ultrasound signal could be picked up but it was impossible to visualize
the entire artery, implicating thrombus obstruction. Outcomewasmea-
sured using a standardized stroke scale. Flow increasewas higher in pa-
tients receiving microbubbles after both 30 (p = 0.03) and 60 min
(p = 0.03) Patients receiving microbubbles signiﬁcantly improved
compared to controls (p = 0.05) [24].Table 1
Neurology— Clinical studies assessing the effect of ultrasound and microbubbles on thromboly
Author(s)/
reference
No. of
patients
Randomization factor Microbubb
Molina et al.
[1]
111 tPA, tPA with US, tPA with US and MB Levovist
Alexandrov
et al. [2]
78 tPA, tPA with US, tPA with US and MB Perﬂutren
Perren et al.
[3]
26 r-tPA with US, r-tPA with US and MB Sonovue
Ribo et al. [4] 18 US, MB rescue treatment Levovist
Rubiera et al.
[5]
138 Type of microbubble used Levovist a
Sonovue
TUCSON trial
[6]
35 r-TPA, r-TPA with US and 1.4 ml MB, r-TPA with
US and 2.8 ml MB
MRX-801
(r)TPA: (reverse) tissue plasminogen activator, US: ultrasound, MB: microbubbles, PW: pulsedAnother study by Ribo et al. used galactose based microbubbles as a
backup to regular treatment. However, in this study, microbubbles and
TPAwere directly injected in the clotted artery through selective cathe-
terization. This intra-arterial technique was used if reperfusion was not
achieved within 1 h after initiation of TPA and ultrasound therapy. Nine
out of 18 patients received this rescue treatment; ﬁve showed complete
recanalization after 12 h, and two showed partial recanalization (78%)
[25].
Molina et al. used MRX-801, a phospholipid-coated perﬂuo-
ropropane microbubble similar to perﬂutren but with a higher concen-
tration of microbubbles, in patients with acute ischemic stroke. In this
randomized prospective trial the ﬁrst cohort treated with ultrasound,
TPA and MRX-801 (n = 12) showed encouraging results, but there
were three cases of intracranial hemorrhage in the second cohort
(n= 11), treated with a two-fold higher dose of microbubbles [26]. Al-
though these patients had severe strokes and may have had other risk
factors for intracranial hemorrhage including hypertension, this study
suggested that higher doses of microbubbles may increase the risk of
hemorrhagic stroke. Although earlier studies already described an
increase in intracranial hemorrhage in some cases, this was largely at-
tributed to the use of low frequency ultrasound (b300 kHz) [27]. A
meta-analysis, using randomized and nonrandomized clinical studies,
performed by Tsivgoulis et al. conﬁrmed the hypothesis that higher ul-
trasound frequencies are less detrimental with a lower odds ratio in the
occurrence of stroke [28]. The occurrence of intracranial hemorrhage
might be attributable to the formation of standing waves when using
low frequency ultrasound and even disruption of the blood–brain barri-
er [29]. A possible higher incidence of intracranial hemorrhage when
using high frequency ultrasound as used in the study by Molina et al.
might be related to the enhanced effectiveness of TPA when adminis-
tered in the presence of microbubbles. This supposition was supported
by subsequent work of Culp et al., in a rabbit model of stroke, which
showed that 1-Mhz ultrasound with TPA and microbubbles increases
recanalization rates compared to ultrasound and TPA alone, without
an increase in the incidence of intracranial hemorrhage [10]. They also
showed effective sonolysis using microbubbles and ultrasound without
TPA in a rabbit stroke model. Less intracranial hemorrhage was ob-
served in animals treatedwithmicrobubbles and ultrasound alone com-
pared to animals also treated with TPA [30]. This reduction was
signiﬁcant compared to earlier human trials with TPA [26,27,31]. If
one assumes that ultrasound andmicrobubbles alonewere effective be-
cause they potentiated the effect of endogenous TPA, these results sug-
gest that human studies of microbubbles and ultrasound in stroke
patients without tPA, or with low dose TPA, merit consideration.
2.4.2. Sonothrombolysis in acute coronary syndromes
Feasibility, efﬁcacy and safety of transtemporal ultrasound and
microbubbles have all been studied in patients with stroke. Howev-
er, sonothrombolysis is still in its early stages of investigation as asis in ischemic stroke patients.
le US settings Outcome
2 MHz Improvement in short-term clinical outcome and
recanalization rate
2 MHz Improvement in (sustained) recanalization rate
2 MHz PW CD,
189 mW/cm2
Improvement in clinical outcome after 24 h when
using
MB (p = 0.05)
2 MHz PW, 750 mW Safe and feasible
nd 1.97 MHz PW,
385 mW/cm2, MI 0.24
No difference between microbubbles
2 MHz, 606 mW/cm2,
MI 0.196
1.4 ml is safe, higher dosage associated with severe
intracranial hemorrhaging
wave, CD: Color Doppler, MI: Mechanical Index.
Table 2
Cardiology— Clinical studies assessing the effect of ultrasound on thrombolysis in STEMI patients.
Author(s)/
reference
No. of
patients
Randomization factor Drugs US settings Outcome
Hamm et al. [1] 14 No randomization NTG, ASA, heparin IVUD, 19.5 kHza Safe and feasible
Rosenschein et al. [2] 15 No randomization IVUD, 45 kHza Safe and feasible
Singh et al. [3] 181 Ultrasound/abciximab Abciximab IVUD, parameters unknown Higher recanalization rate with
abciximab
Cohen et al. [4] 25 No randomization Reteplase or tenecteplase TTE, 27 kHz continuous ultrasound,
0.9 W/cm2
Safe and feasible
PLUS trial [5] 360 Ultrasound ASA, heparin or enoxaparin. Tenecteplase TTE, PW, 0.12 W/cm2 Decrease in ST elevation at 90 min
Slikkerveer et al. [6] 10 Microbubble
(Luminity ®)
ASA, heparin, alteplase TTE, 1.6 MHz 3D, MI 1.18,
max 26 mW/cm2
Safe and feasible
(r)TPA: (reverse) tissue plasminogen activator, US: ultrasound, PW: pulsedwave,MI:Mechanical Index,MB:microbubble, NTG, nitroglycerin, ASA; acetylsalicylic acid, IVUD; intravascular
ultrasound device, TTE; transthoracic echocardiogram.
a Catheter-based invasive ultrasound therapy.
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formed using intravascular catheter based sonothrombolysis in pa-
tients with STEMI. Both studies used low ultrasound frequencies
(19.5 and 45 kHz), applied directly before PCI. PCI was only per-
formed if TIMI grade was below three after ultrasound application.
The ﬁrst study showed that intravascular ultrasound improved
TIMI ﬂow by at least 1 grade in 13 out of 14 patients [4]. The second
study utilizing 45 kHz ultrasound showed that TIMI 3 ﬂow prior to
PCI was achieved in 86% of patients (total n = 15) [32].
The ATLAS studywas performed in STEMI patients with an occluded
saphenous vein bypass graft (SVBG) and treatedwith either intravascu-
lar therapeutic ultrasound (n=92) or abciximab (n=91), both follow-
ed by PCI. It was shown that ultrasound alone was capable of opening a
clotted SVBGwith a success rate of 63%, while patients whowere under
treatment with abciximab alone showed a higher recovery rate of 82%
(p = 0.008). Also, patients treated with ultrasound alone had a higher
incidence of major adverse cardiac events compared to abciximab
(p = 0.036), but this result is confounded by a higher incidence of Q-
wave myocardial infarction in the ultrasound group. The trial was ter-
minated prematurely because of these observations [33].
Later research focused on the transthoracic application of therapeu-
tic ultrasound. Cohen et al. published results from a transthoracic ultra-
sound feasibility and safety testing study. A total of 25 patients received
reteplase (n = 15) or tenecteplase (n = 10), and all patients received
transcutaneous ultrasound therapy. A low frequency of 27 kHz was
used in this trial, combined with a skin cooling system. Therapy started
within 30min after arrival in the hospital and continued for 60min. Af-
terwards, coronary angiographywas performed to assess TIMIﬂow. The
results demonstrated that 64% of patients had TIMI 3 ﬂow after ultra-
sound therapy. Ultrasound parameters were changed after 15 patients,
because 3 patients developed skin blistering. These parameters have
not been speciﬁed by the authors. This study showed the technique to
be safe and feasible [3].
Based on promising results in the previously described and other
earlier in-vitro and in-vivo studies [34–37], a large double blind ran-
domized controlled trial was conducted in 391 patients with STEMI. Pa-
tients were randomized to either thrombolysis (n = 182) or
thrombolysis with transthoracic low frequency ultrasound (n = 178).
All patients were treated with aspirin, unfractionated heparin or
enoxaparin, and either reteplase or tenecteplase. The ultrasound
group received 60 min of low frequency ultrasound (28.3 kHz) with a
spatial peak pulse average intensity of 0.38 W/cm2, unless worsening
occurred and patients required resuscitation or angiography. Patients
in the control group were attached to the same ultrasound generator
plus a sham transducer and experienced mild warmth and vibration.
Primary end points were achieving TIMI grade 3 ﬂow and N50% cumu-
lative ST-segment resolution after 60 min of thrombolytic administra-
tion. This trial was terminated prematurely because no difference was
detected in the treatment groups during interim analysis. No signiﬁcant
difference in adverse cardiac events was observed. However, asigniﬁcant difference in a 90 minute ST segment resolution was found
in favor of the ultrasound treated group. Part of the population included
in this speciﬁc statistical analysis had already received primary PCI
when ST segment resolution was measured. Nonetheless, the authors
conclude that this might be because of an improvement in myocardial
tissue perfusion [5], whichwas also observed with low frequency ultra-
sound in vivo [38].
Recently, a pilot study was performed, experimenting on the con-
cept of microbubble enhanced sonothrombolysis in STEMI. A low dose
thrombolytic therapy was combined with primary PCI and compared
to the addition of microbubble enhanced sonothrombolysis in acute
STEMI patients. The pilot study evaluated the effectiveness and feasibil-
ity of microbubble treatment in a clinical setting in patients with STEMI.
Ten patients were included, equally randomized into treatment or con-
trol groups. A 3D echotransducer with a frequency of 1.6MHzwas used.
First results show a non-signiﬁcant difference in TIMI 3 ﬂow rates
achieved before PCI between control (1 out of 5 patients) and treatment
(3 out of 5 patients) groups. Because of the low number of patients in-
cluded thus far, no statistical difference in epicardial coronary recanali-
zation rate was observed and no difference in cardiac function was
observed during follow-up. No serious adverse events occurred and
the study design was deemed feasible and safe [11].
3. Discussion
In ischemic strokepatients, sonothrombolysiswithoutmicrobubbles
have shown a varying degree of success [19,31] when using pulsed
wave Doppler transducers. However, in the lower ranges of ultrasound
frequencies (b1 MHz), there is a higher risk of intracranial hemorrhage
[27]. When microbubbles are added and higher frequencies were used,
the technique proved to be relatively safe and feasible with clinical re-
covery rates signiﬁcantly higher when compared to controls [9,22,
24–26]. Almost all studies thus far have used a sonothrombolysis treat-
ment combinedwith a full dose (recombinant) tPA therapy. Low and no
dose tPA experiments are successful in animal models, showing a de-
crease in systemic side-effects, especially bleeding, while maintaining
a local sonothrombolytic effect [10,30]. Studies treating patients with
low dose ﬁbrinolytic regimens combined with ultrasound and
microbubbles should be designed next to achieve a balance between ef-
ﬁcacy and bleeding risk.
Case–control studies evaluating the effect of microbubbles and
sonothrombolysis in patients with a myocardial infarction are scarce.
A number of clinical trials have been performed comparing
sonothrombolysis without microbubbles with standard thrombolytic
therapy, and the results are not consistent. Few clinical studies have
been performed in STEMI patients using sonothrombolysis. A large
trial was aborted because of lack of effect [5], but two smaller trials
showed promising results [3,39]. Three trials used low frequency thera-
peutic ultrasound (19.5, 27 and 45 kHz) not registered for clinical diag-
nostic use. Two of these used intracatheter ultrasound devices to
5S.T. Roos et al. / IJC Heart & Vessels 4 (2014) 1–6achieve a thrombolytic effect prior to PCI. While no comparison was
made with control patients, clinical safety results and the high percent-
age of restoration to TIMI 3 ﬂow are encouraging.
All STEMI trials focused on epicardial recanalization of blood ﬂow.
Ultrasound guided cavitation might also target microvascular recanali-
zation. The amount of no-reﬂow was not measured in any study using
sonothrombolysis. No-reﬂow occurs in up to 40% of patients with
acute ST segment elevationmyocardial infarction despite successful pri-
mary PCI and leads to further impairment of the left ventricle and sub-
sequent complications such as the development of heart failure [40,
41]. This has an impact on the quality of life, higher use of medication
and more hospital admissions. Furthermore, it also leads to an increase
inmortality [42]. Pre-clinical trials are already underway examining the
effect of microbubble enhanced sonothrombolysis in microthrombi oc-
cluding the distal microvascular arteries.
Transthoracic and transcranial echography was performed most
often in the studies described in this review. Almost all investigators
used 2D transducers where sweeps are necessary to achieve full effect.
The relatively new 3D transducers might prove to be of additional ben-
eﬁt, continuously able to target a bigger area in which cavitation occurs.
A larger ﬁeld of effect might be beneﬁcial in a patient population where
the culprit lesion is not yet known or found. Future studies should com-
pare both 2D and 3D transducers.
Regarding pulse duration, one experimental in-vivo atherosclerotic
pig study compared a 5 second pulse duration with a 20 second pulse
duration in a situation of acute myocardial infarction by thrombotic oc-
clusion. An improvement was visible suggesting a beneﬁt to increasing
pulse duration [43]. The pilot study in STEMI patients uses a 5 second
pulse duration and while we await further results, studies should con-
sider using a longer pulse duration to improve microbubble enhanced
sonothrombolytic effect.
In a clinical setting, the diagnostic frequencies used with a trans-
thoracic ultrasound transducer have been utilized effectively during
treatment with sonothrombolysis. Their imaging capabilities permit
detection of microbubbles within the microvasculature, providing
information about replenishment of microbubbles after the applica-
tion of a therapeutic high MI impulse and thus allowing optimal ap-
plication of a new therapeutic impulse. When using simultaneous
low MI imaging to guide and optimally time the therapeutic im-
pulses, more microbubbles are available for cavitation, enhancing
the effect of sonothrombolysis. Such image guidance may also be
critical to the safe and effective application of sonothrombolysis in
stroke and treatment of other vascular thromboses because the ul-
trasound beam can be aimed directly to the area of interest.
Future clinical application of sonothrombolysis might also en-
compass a broad scale of medical disciplines, e.g. in vascular
atherothrombotic disease or venous thromboses. Pre-hospital treat-
ment with sonothrombolysis in acute coronary syndromes might be
used as a neoadjuvant therapy to primary percutaneous coronary in-
terventions. This is especially true for countries that are no longer
using thrombolytic treatment in STEMI patients due to readily avail-
able specialized PCI centers. Sonothrombolysis might also be more
effective compared to TPA in a setting of chronic thrombosis, as
TPA is optimally used in acute thrombi and rapidly loses efﬁcacy
when a thrombus ages [44].
4. Conclusion
Thrombolysis can be enhanced using microbubble accelerated
sonothrombolysis. This has been shown extensively in ischemic stroke
patients. There is evidence that this treatment option improves out-
come in patients with ischemic stroke, dissolving these clots and im-
proving clinical and long-term outcome while possibly reducing
bleeding risk.
Few, very heterogeneous, studies exist examining the effect of ultra-
sound induced cavitation of microbubbles on human patients withSTEMI. The technique of sonothrombolysis shows a theoretical promise
as an adjunctive treatment to PCI but needs to be studied inmore detail.
Additionally, sonothrombolysis might be used after PCI to lower the in-
cidence of no-reﬂow in patients.
Ultrasound parameters used should be carefully considered when
designing a clinical trial. Clearly, improvements in therapeutic transduc-
ers are needed, and these therapeutic transducers must be combined
with diagnostic imaging to optimize ultrasound induced cavitation
events. Randomized prospective trials are needed to further evaluate
this new frontier of therapeutic ultrasound, which could then lead to
its safe application early in the treatment of acute stroke or acute coro-
nary syndromes.
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